Correction to: ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.